From Nasdaq: 2025-06-06 20:42:00

BioCryst Pharmaceuticals’ ORLADEYO receives national reimbursement in the Netherlands for routine prevention of hereditary angioedema attacks in patients aged 12 and above. The oral, once-daily preventive treatment is now covered in all major European countries. ORLADEYO, a plasma kallikrein inhibitor, is available in over 30 countries and is not approved for acute treatment. Common side effects include gastrointestinal symptoms and back pain. Caution is advised for patients with hepatic impairment and potential drug interactions. ORLADEYO’s safety in certain populations is still under study. BCRX stock closed at $11.04 on Thursday, up 0.55%.



Read more at Nasdaq: BioCryst’s ORLADEYO Gains Full EU Reimbursement Approval With Netherlands Inclusion